Liu, S.; Yan, S.; Zhu, J.; Lu, R.; Kang, C.; Tang, K.; Zeng, J.; Ding, M.; Guo, Z.; Lai, X.;
et al. Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab. Int. J. Mol. Sci. 2022, 23, 9014.
https://doi.org/10.3390/ijms23169014
AMA Style
Liu S, Yan S, Zhu J, Lu R, Kang C, Tang K, Zeng J, Ding M, Guo Z, Lai X,
et al. Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab. International Journal of Molecular Sciences. 2022; 23(16):9014.
https://doi.org/10.3390/ijms23169014
Chicago/Turabian Style
Liu, Shujie, Shuai Yan, Jie Zhu, Ruiqing Lu, Chujie Kang, Kang Tang, Jinfeng Zeng, Mingmei Ding, Zixiang Guo, Xianxin Lai,
and et al. 2022. "Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab" International Journal of Molecular Sciences 23, no. 16: 9014.
https://doi.org/10.3390/ijms23169014
APA Style
Liu, S., Yan, S., Zhu, J., Lu, R., Kang, C., Tang, K., Zeng, J., Ding, M., Guo, Z., Lai, X., Jiang, Y., Wu, S., Zhou, L., Sun, L., & Zhou, Z.-W.
(2022). Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab. International Journal of Molecular Sciences, 23(16), 9014.
https://doi.org/10.3390/ijms23169014